Browsing tag:

percutaneous coronary intervention


Clopidogrel Bisulfate, also known as the brand name anticoagulant medication Plavix, continues to impress with its safety profile. A study released at the end of March 2013 revealed that patients set to undergo percutaneous coronary intervention could successfully continue their regimen of Clopidogrel during this time. Caution was extended from the study investigators, which took[…]

Read More

Known as the brand name Effient, Prasugrel was approved by the FDA in July of 2009 as a blood thinning drug. Designed to be used to reduce the risk of blood clots from forming in patients who undergo angioplasty, which is a common procedure to unblock a clogged coronary artery, Prasugrel was studied in close[…]

Read More

Eptifibatide, CAS# 188627-80-7, is an antiplatelet agent. Also offered from LGM Pharma as a TEVA API (TAPI) product for compounding purposes, eptifibatide is also known by the brand name Integrilin, which is marketed by Merck. With Merck’s patent for Integrilin due to expire on November 11, 2014, and an additional patent revision due to expire[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service